Resverlogix has exceeded the enrolment target of more than 2,400 patients in its Phase III BETonMACE trial, evaluating the effect of its drug, apabetalone, in Cardiovascular Disease (CVD) patients with type 2 Diabetes Mellitus (DM) and low high-density lipoproteins (HDL).

The pivotal trial enrolled its first patient in November 2015.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

“Achieving full enrolment early leaves two major clinical reflection points that will transpire in 2018.”

Its primary endpoint is to establish a relative risk reduction (RRR) of major adverse cardiac events (MACE), narrowly defined as a single composite endpoint of cardiovascular death, non-fatal myocardial infarction (MI) and stroke.

Secondary pre-specified objectives of the trial include the analysis of renal function and MACE in patients with chronic kidney disease (CKD) stage three as well as cognition, measured by the Montreal Cognitive Assessment (MoCA) in all patients aged 70 and over.

Resverlogix president and CEO Donald McCaffrey said: “Achieving full enrolment early leaves two major clinical reflection points that will transpire in 2018.

“The first will be attaining 75% of our targeted 250 MACE events, being 188 events in total, thus allowing us the ability to conduct a sample size re-estimation analysis assuring that the trial will be sufficiently powered to confirm relative risk reduction.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The second major reflection point will be the most important, the Primary Endpoint read-out around the end of 2018. This read-out will prove pivotal in planning our FDA and EMA registration applications.”

Resverlogix said it is exploring the option of enrolling patients in the US for the BETonMACE trial.

It also intends to explore the option of relying on existing BETonMACE data to file a US New Drug Application (NDA) for apabetalone.

Apabetalone (RVX-208) is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor.